18F-FDG-PET/CT in Patients with Advanced, Radioiodine Refractory Thyroid Cancer Treated with Lenvatinib.
Freba AhmaddyCaroline Alexandra BurgardLeonie BeyerViktoria Florentine KoehlerPeter BartensteinMatthias Philipp FabritiusThomas GeyerVera WenterHarun IlhanChristine SpitzwegAndrei TodicaPublished in: Cancers (2021)
Tumor response assessment by 18F-FDG-PET outperforms morphological response assessment by CT in patients with advanced radioiodine refractory DTC treated with Lenvatinib, which seems to be correlated with clinical outcomes.